TCTR20170727001尚未招募未知
Incidence of cutaneous complications in advanced solid cancer patient treated with epidermal growth factor receptor inhibitors
Quality Improvement Fund, King Chulalongkorn Memorial Hospital0 个研究点目标入组 110 人开始时间: 2017年7月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 0 N/A (No limit)（—）
- 性别
- All
入选标准
- •- advanced solid cancer patients (stage IV) treated with epidermal growth factor receptor inhibitors
- •- above 18 years old
排除标准
- •prior to recruit in the study, patients have existing skin conditions including acneiform eruption, paronychia, hair abnormalities, skin dryness and pruritus.
研究者
相似试验
尚未招募
不适用
Rate of severe cutaneous adverse reactions due to first line Anti-tuberculosis drugs, Health Product Vigilance Center database; Food and Drug Administration, Ministry of Public Healthsevere cutaneous adverse reactionsSCARscutaneous adversed reactionsantituberculosisfirst line antituberculosis drugsSJSTENDRESSAGEPsevere cutaneous adverse reactionsSCARscutaneous adversed reactionsantituberculosisfirst line antituberculosis drugsDRESSAGEPSJSTENTCTR20180812003Tipsiri Chaikong3,500
已完成
不适用
Study for association with dermatological adverse event induced by molecular targeted drugs and profile of body weigh dispersiometastatic renal cell cancerJPRN-UMIN000018948Department of Pharmacy, Kobe University Hospital30
Unknown
2 期
Acute skin toxicity and cosmesis outcome in ultrahypofractionated radiotherapy for non metastatic breast cancer treated with proton radiotherapy compared with photon radiotherapyon metastatic breast cancerUltrahypofractionProton radiotherapyNon metastatic breast cancerAcute skin toxicityTCTR20210219004ational research and innovation information system140
尚未招募
不适用
clinical and histopathological study of drug reactions in skiCTRI/2020/03/023893Dr Amulya s
招募中
不适用
Association between cutaneous manifestations and mutation gene by whole exome sequencing technique among neurofibromatosis type 1 patientsNF1neurofibromatosis type 1TCTR20220706007Health Systems Research Institute40